Ciblage diagnostique par Hexvix® des tumeurs urothéliales de vessie : résultats après quatre ans d'évaluation prospective monocentrique

In our experience, Hexvix® targeting was associated with better diagnosis for bladder cancer with 9% (13/144) of new positive samples (P = 0.003). In our study, false positive rate is a critical point (53.4%). Multifocality, previous TCC, and EORTC score for recurrence and progression might allow selecting patients to be targeted by Hexvix®.